Dealing by Person Closely Associated

1 November 2016 15:30

Transaction by Person Closely Associated with a Person Discharging Managerial Responsibilities

Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation

On 31 October 2016, Mrs Susan Chipchase notified us that, on 27 October 2016, she purchased 100 AstraZeneca PLC Ordinary Shares of US$0.25 each at a price of £48.08 per share.

Mrs Chipchase is a person closely associated with Graham Chipchase, a Non-Executive Director of AstraZeneca PLC.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of   the person discharging managerial responsibilities / person closely   associated
a) Name Susan Chipchase
2 Reason for   the notification
a) Position/status Person Closely Associated with a Person   Discharging Managerial Responsibilities (PDMR) in respect of AstraZeneca PLC
b) Initial notification /Amendment Initial notification
3 Details of   the issuer, emission allowance market participant, auction platform,   auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI Not applicable
4 Details of   the transaction(s): section to be repeated for (i) each type of instrument;   (ii) each type of transaction; (iii) each date; and (iv) each place where   transactions have been conducted
a) Description of the financial instrument, type of   instrumentIdentification code Ordinary Shares of US$0.25 each in AstraZeneca   PLCGB0009895292
b) Nature of the transaction Acquisition
c) Price(s) and volume(s) Price(s) Volume(s)
4807.95 pence 100
d) Aggregated information- Aggregated volume- Price Not applicable - single transaction
e) Date of the transaction 27 October 2016
f) Place of the transaction London

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media   Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor   Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711
US toll free +1 866 381 7277

Adrian Kemp
Company Secretary, AstraZeneca PLC

-ENDS-

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links